William G. Gunn

William G. Gunn

Auto-generated profile, based on publicly available information

William G. Gunn

Center for Gene Therapy, and Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2010 in IEEE Journal of Selected Topics in Quantum Electronics
Verified
Journal Article
Closed access
MIMuzammil Iqbal
Muzammil Iqbal
MGMartin A Gleeson
Martin A Gleeson
BSBradley Spaugh
Bradley Spaugh
FTFrank Tybor
Frank Tybor
WGWilliam G. Gunn
William G. Gunn
LGL. Cary Gunn
L. Cary Gunn
A platform for performing rapid, real-time binding assays on sensor arrays based on silicon ring resonators is presented in this paper. An array of 32 sensors is interrogated simultaneously. Using eight sensors as controls, 24 simultaneous binding curves are produced. The bulk refractive index sensitivity of the system was demonstrated down to 7.6 × 10-7 and sensor-to-sensor variability is 3.9%. Using an 8-min incubation, real-time binding was observed over 8-logs of concentration down to 60 fM using immobilized biotin to capture streptavidin diluted in bovine serum albumin solution. Multiplexing in complex media is demonstrated with two DNA oligonucleotide probes. Time to result and repeatability are demonstrated to be adequate for clinical applications.

1 April 2006 in Stem Cells
Verified
Journal Article
Open access
PDF file
WGWilliam G. Gunn
William G. Gunn
ACAdam Conley
Adam Conley
LDLisa Deininger
Lisa Deininger
SOScott D. Olson
Scott D. Olson
DPDarwin J. Prockop
Darwin J. Prockop
CGCarl A. Gregory
Carl A. Gregory
Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells. B-cell plasmacytomas stimulate bone resorption and angiogenesis, resulting in osteolytic lesions in the skeleton which persist upon successful treatment of the malignancy with chemotherapy. We found that an interaction between MM cells and mesenchymal stem cells (MSCs) from bone marrow stroma results in the formation and persistence of osteolytic bone lesions. It is known that MM cells activate osteoclast activity and secrete high levels of the Wnt inhibitor, Dickkopf-1, which prevents MSCs from differentiating into osteoblasts. We show that the Wnt signaling activator 6-bromoindirubin-3′-monoxime (BIO) releases MSCs from the osteoinhibitory effects of Dickkopf-1, whereas LiCl treatment does not. Additionally, we show that the >5-kDa fraction of MSC-conditioned medium promotes the proliferation of Dickkopf-1-secreting MM cells and that an interleukin-6 (IL-6)-neutralizing antibody blocks this effect. IL-6 expression levels were higher in undifferentiated MSCs than in MSCs treated with osteogenic medium, remained high in the presence of Dkk1, and were reduced by BIO treatment. Therefore, BIO treatment reduces the MSC-stimulated proliferation of MM cells and may enable MSCs to repair existing osteolytic lesions.

1 May 2005 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CGCarl A. Gregory
Carl A. Gregory
WGWilliam G. Gunn
William G. Gunn
EREmigdio Reyes
Emigdio Reyes
ASAngela J. Smolarz
Angela J. Smolarz
JMJames Munoz
James Munoz
DPDarwin J. Prockop
Darwin J. Prockop

1 January 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CGCarl A. Gregory
Carl A. Gregory
APAnthony S. Perry
Anthony S. Perry
EREmigdio Reyes
Emigdio Reyes
ACAdam Conley
Adam Conley
WGW. Grady Gunn
W. Grady Gunn
DPDarwin J. Prockop
Darwin J. Prockop
It is established that human mesenchymal stem cells (hMSCs) from bone marrow are a source of osteoblast progenitors in vivo and under appropriate conditions, differentiate into osteoblasts ex vivo. Because hMSCs are recovered by iliac crest aspirate and enriched by virtue of their adherence to tissue culture plastic, the cells provide a convenient ex vivo model for the study of osteogenic tissue repair in an experimentally accessible system. Recent advances in the field of skeletal development and osteogenesis have demonstrated that signaling through the canonical wingless (Wnt) pathway is critical for the differentiation of progenitor cell lines into osteoblasts. Inhibition of such signals can predispose MSCs to cell cycle entry and inhibit osteogenesis. Here, we report that synthetic peptides derived from the second cysteine-rich domain of the canonical Wnt inhibitor Dickkopf-1 (Dkk-1) have utility in controlling the growth and recovery of hMSCs from bone marrow stroma. Three peptides corresponding to residues 217–269 in Dkk-1 were each found to enhance the proliferation of hMSCs in culture over 2 days. The most active peptide exhibited agonistic characteristics in that it ablated the proliferation lag observed when cultures of hMSCs receive fresh medium. It also reduced the expression of endogenous Dkk-1 (Gregory, C. A., Singh, H., and Prockop, D. J. (2003) J. Biol. Chem. 278, 28067–28078). When the cytosolic level of β-catenin was elevated by addition of LiCl to cultures of hMSCs, the peptide also accelerated degradation of β-catenin on withdrawal of lithium. A second peptide, corresponding to residues 184–204 had preferential and high affinity for hMSCs in the log phase of proliferation. Peptide overlay assays on hMSC lysates confirmed that the peptide bound to a 184-kDa protein corresponding to the molecular mass of LRP6. Cells recovered by this peptide had enhanced osteogenic potential but less chondrogenic potential compared with controls. Because Wnt antagonists increase the number of non-committed hMSCs in culture, they may be of use in increasing the rate of osseous wound healing in vivo by increasing the level of systemically migrating hMSCs. Therefore, such molecules could contribute to the development of a novel family of pharmaceutical agents for the improvement of the healing process in humans.

3 February 2011 in Blood
Verified
Journal Article
Closed access
PDF file
WGW. Grady Gunn
W. Grady Gunn
UKUlf Krause
Ulf Krause
NLNarae Lee
Narae Lee
CGCarl A. Gregory
Carl A. Gregory
Multiple myeloma (MM) is a malignancy of plasma cells that accumulate in the bone marrow. MM is incurable with approximately 100 000 patients currently in the United States and 20 000 new cases diagnosed yearly. The malignancy causes displacement of hematopoiesis and formation of osteolytic bone lesions also known as myeloma bone disease (MBD). At diagnosis, 79% of patients suffer from MBD associated with severe pain and increased mortality. Wnt inhibitors secreted by MM cells inhibit osteogenesis and promote osteoclastogenesis, therefore rapid targeting of Wnt inhibitors is necessary to prevent potentially irreversible effects on the stroma, which could lead to incurable MBD. Inhibition of glycogen synthetase kinase-3β (GSK3β) causes accelerated Wnt signaling and enhanced osteogenesis in mesenchymal stem/progenitor cells, irrespective of the extracellular concentration of Wnt inhibitors. Our primary goal of this study was to evaluate a GSK3β inhibitor (6-bromoindirubin-3′-oxime BIO) for amelioration of bone destruction in a murine model of MBD. When measured using histomorphometry, peritumoral BIO administration improved bone quality at the bone-tumor interface and, surprisingly, increased histologically apparent tumor necrosis. Furthermore, in vitro assays demonstrated a proapoptotic effect on numerous MM cell lines. These preliminary data suggest that pharmaceutical GSK3β inhibition may improve bone quality in myeloma and other malignant bone diseases.

1 January 2006 in Drug News & Perspectives
Verified
Journal Article
Closed access
CGC.A. Gregory
C.A. Gregory
AGA. Green
A. Green
NLN. Lee
N. Lee
ARA. Rao
A. Rao
WGW. Gunn
W. Gunn